1. Home
  2. RDI vs MRKR Comparison

RDI vs MRKR Comparison

Compare RDI & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDI

Reading International Inc

HOLD

Current Price

$1.05

Market Cap

24.1M

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.49

Market Cap

24.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDI
MRKR
Founded
1937
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.1M
24.5M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
RDI
MRKR
Price
$1.05
$1.49
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$10.17
AVG Volume (30 Days)
27.6K
191.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$13.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$0.81
52 Week High
$1.65
$4.07

Technical Indicators

Market Signals
Indicator
RDI
MRKR
Relative Strength Index (RSI) 45.96 45.66
Support Level $1.00 $1.37
Resistance Level $1.16 $1.88
Average True Range (ATR) 0.06 0.12
MACD -0.00 0.00
Stochastic Oscillator 55.81 47.89

Price Performance

Historical Comparison
RDI
MRKR

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Share on Social Networks: